Durable outcomes were reported standard-dose tivozanib monotherapy in second- and third-line metastatic RCC.
Commentary|Articles|June 9, 2026
GU Cancer Experts Highlight the Most Impactful and Discussion-Worthy Data Presented at ASCO 2026
Author(s)Kyle Doherty
Fact checked by: Courtney Flaherty, Tracy Ann Politowicz
ASCO 2026 genitourinary experts unpack key prostate and bladder cancer data, revealing practice-changing takeaways and what they mean for patient care.
Advertisement
Advertisement
OncLive® connected with genitourinary oncology experts at the
Related to this article
Darlifarnib plus cabozantinib showed durable responses and manageable safety in cabozantinib-naive advanced clear cell RCC.
A post-hoc analysis of LITESPARK-005 found that higher baseline and improved on-treatment QOL scores tracked with lower risk of disease progression and death.
lan M. Thompson Jr., MD, discusses the potential role of 5-ARIs for the treatment of patients with prostate cancer.
Dostarlimab monotherapy produced a 27% response rate in PD-L1-positive recurrent/metastatic head and neck squamous cell carcinoma
Early nivolumab responders sustained years-long treatment-free survival after treatment discontinuation.
Adding an IL-15 receptor superagonist to a vaccine plus bintrafusp alfa produced clinical responses in pMMR CRPC.
Natera has submitted Signatera to Japan's PMDA for approval as a companion diagnostic in muscle-invasive bladder cancer.
Advertisement
Advertisement